|
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
RECRUITINGEarly 1Sponsored by RayzeBio, Inc.
Actively Recruiting
PhaseEarly 1
SponsorRayzeBio, Inc.
Started2026-06-15
Est. completion2027-08
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07671092
Summary
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Are at least 18 years old at the time of signing the informed consent form (ICF) * Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC Exclusion Criteria: * For Women of Childbearing Potential: Are pregnant or breastfeeding Note: Additional criteria may apply and will be assessed by the study site
Conditions7
Breast CancerCancerHormone Receptor Positive HER-2 Negative Breast CancerLung CancerMetastatic Urothelial CarcinomaNSCLCTNBC - Triple-Negative Breast Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseEarly 1
SponsorRayzeBio, Inc.
Started2026-06-15
Est. completion2027-08
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07671092